Seeking Alpha

A long-term Phase III study confirms the safety of Pfizer's (PFE) ALO-02 capsules for treating...

A long-term Phase III study confirms the safety of Pfizer's (PFE) ALO-02 capsules for treating patients with moderate-to-severe chronic, non-cancer pain. The "adverse event profile" was as expected, with the most common side effects - in over 10% of the 395 patients in the study - being nausea, constipation, vomiting and headache. (PR)
Comments (1)
  • Joseph P. Porter
    , contributor
    Comments (813) | Send Message
     
    The side effects are no news to the medical community and anyone who is being treated for chronic pain - as is my spouse. All serious pain meds have the same side effects. In fact, that only 10% of the trial patients were affected is on the good side of the news.
    11 Oct 2012, 11:07 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs